Additionally, ultrasensitive quantification of SAM-derived methyl groups will further elucidate differences in DNA, RNA, and histone protein methylation to provide insight into whether SAM-mediated epigenetic modifications through MAT1A provide cancer cells with a drug resistant phenotype. The gene discussed is MAT1A; the disease is cancer.